NAB-BC-3781-1202: A Phase 1, Open-Label, Two-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Intravenous Lefamulin in Hospitalized Pediatric Subjects Receiving Standard of Care Antibiotic Therapy for Confirmed or

Project: Research project

Project Details

Effective start/end date6/11/208/31/50


  • Nabriva Therapeutics Ireland DAC
  • Nabriva Therapeutics Ireland DAC